Loading organizations...
§ Venture Capital · Seattle, WA, USA
Venture capital firm investing in early-stage healthcare and life sciences startups, focused on genomics, digital health, and AI.
Key people at Biomatics Capital Partners.
Biomatics Capital Partners is a venture capital firm based in Seattle, Washington, that invests in early-stage healthcare technology and life sciences startups operating at the intersection of biology, data, and artificial intelligence. The firm manages approximately $500 million in assets under management across its flagship vehicles, including a $300 million second healthcare fund closed in 2018. Targeting seed to Series B stages, the firm provides capital to companies developing innovations in genomics, diagnostics, and digital health, such as leading a $120 million Series B round for Editas Medicine before its $94.4 million initial public offering. Its broader investment portfolio features prominent biotechnology and therapeutics developers, including GRAIL, Denali Therapeutics, Neumora, and eGenesis, which recently secured a $125 million Series C funding round. Biomatics Capital Partners was founded in 2016 by Boris Nikolic and Julie Sunderland.
Key people at Biomatics Capital Partners.
Biomatics Capital Partners is a Seattle-based venture capital firm focused on investing in transformative, data-enabled innovations at the intersection of healthcare and technology. Their mission centers on advancing breakthroughs in genomics, digital health, diagnostics, therapeutics, and healthcare delivery models to drive a value-based healthcare system that lowers costs and improves patient outcomes. The firm primarily targets early-stage companies pioneering disruptive technologies in genomics and digital health, leveraging deep technical expertise and a strong network of academics, pharma executives, and venture capitalists to support portfolio growth and impact the startup ecosystem positively[1][2][3].
Founded in 2016 by Dr. Boris Nikolic and Julie Sunderland, Biomatics Capital has evolved its focus around the convergence of genomics and digital data, recognizing this as a tipping point for healthcare innovation. The partners bring extensive experience in technology, healthcare, and life sciences investing, which has enabled them to back notable companies such as Editas Medicine, a leader in CRISPR gene editing. Their early involvement in Editas included leading a $120 million Series B round and guiding the company to a successful $94.4 million IPO, underscoring their ability to identify and nurture breakthrough science from early stages to market leadership[1][2][4][6].
Biomatics Capital rides the wave of convergence between genomics and digital health, a trend reshaping medicine into a value-based system focused on precision and efficiency. The timing is critical as advances in gene editing, DNA synthesis, and digital diagnostics unlock new therapeutic possibilities and healthcare delivery models. By backing companies that leverage big data and genomics, Biomatics influences the broader ecosystem by accelerating innovation that promises lower healthcare costs and better patient outcomes, thus helping to transform the healthcare industry at large[3][6].
Looking ahead, Biomatics Capital is poised to continue leading investments in cutting-edge healthcare technologies, particularly as genomics and digital health mature further. Their recently closed $300 million second healthcare fund signals confidence in ongoing breakthroughs in diagnostics, therapeutics, and clinical care innovation. Trends such as personalized medicine, AI-driven diagnostics, and gene editing will likely shape their portfolio and influence. Biomatics’ role as a strategic partner and network hub will remain crucial in helping startups navigate complex scientific and regulatory landscapes, reinforcing their position as a key driver of transformative healthcare innovation[1][2][6].
In summary, Biomatics Capital Partners stands out as a visionary venture firm dedicated to transforming healthcare through data-enabled innovation, combining deep scientific insight with strategic investment to foster the next generation of breakthrough medical technologies.
Biomatics Capital Partners has more than 26 tracked investments across 10 companies. The latest tracked deal is $92.0M Series C in Be Biopharma in January 2025.
